Moderna requests emergency FDA authorization for COVID-19 vaccine

Article

Moderna announced yesterday its plan to apply for emergency FDA authorization for its COVID-19 vaccine candidate.

Moderna also reported that the primary efficacy analysis of its phase 3 COVE study of mRNA-1273 demonstrated a high efficacy rate of 94.1%, with a 100% efficacy rate against severe COVID-19. A total of 196 cases of COVID-19, including 30 severe cases, among 30,000 participants were included in the analysis.

Vaccine efficacy was initially reported at the first interim analysis with a total of 95 cases based on pre-specified success criteria on efficacy. Today’s primary analysis was based on the 195 cases, of which 185 cases were observed in the placebo group versus 11 cases in the mRNA-1273 group. The primary end point is based on the analysis of COVID-19 cases confirmed and adjudicated starting 2 weeks following the second dose of the vaccine.

Continue reading this article on Drug Topics.

Newsletter

Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.

Recent Videos
Jihong Liu, ScD, explains how to improve perinatal outcomes in COVID patients | Image Credit: sc.edu.
Jihong Liu, ScD, highlights adverse perinatal outcomes linked to the COVID pandemic | Image Credit: sc.edu.
COVID-19 Therapy Roundtable: Focusing on inpatient care
COVID-19 Therapy Roundtable: Defining the virus today and treatment options
The importance of maternal vaccination | Image Credit: nfid.org.
Jeanette Carpenter, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.